TNFRSF1B and neoplasm: Inhibition of transmembrane TNF-TNFR2 impaired the IL-6/STAT3 signaling pathway in the tumor and diminished the iCAF:myCAF ratio, ultimately attenuating the inflammatory stromal components and fibrotic collagen deposition.